Biodesix now carries a higher fair value estimate, with the assessed price target moving from US$34 to US$39, which is about a 15% change in the latest model. Recent analyst commentary links this shift to interest in the company's Molecular Residual Disease offerings and broader diagnostics exposure, as well as recognition of execution and reimbursement questions that still exist. In the sections that follow, you will see how these moving pieces shape the evolving Biodesix narrative and what to watch as new information arrives.
Stay updated as the Fair Value for Biodesix shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Biodesix.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
TD Cowen raised its Biodesix price target to US$40 from US$30 in an October 2026 Q3 earnings preview, citing large addressable markets, what it calls rapid volume growth, and margin opportunities that it views as supportive into upcoming results.
-
H.C. Wainwright increased its Biodesix target twice in recent months, first to US$27 from US$26 in August 2026 and then to US$38 from US$27 in late September, pointing to Molecular Residual Disease offerings and expanded patient coverage through both tumor informed and tumor naive assays.
-
H.C. Wainwright also highlighted Q2 revenue at Biodesix alongside slower growth in operating expenses, which the firm characterized as encouraging for profitability efforts.
-
Craig Hallum indicated that the proposed 2027 CMS clinical laboratory fee schedule would have what it views as an immaterial impact on Biodesix, which may help reduce concern about reimbursement pressure relative to some peers.
🐻 Bearish Takeaways
-
While none of the firms in recent commentary adopt a negative stance on Biodesix, TD Cowen and H.C. Wainwright both frame their views within broader diagnostics sector moves and reimbursement discussions, which can leave investors sensitive to execution and policy developments from here.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 3 risks for Biodesix. See which could impact your investment.
How This Changes the Fair Value For Biodesix
-
Fair value for Biodesix has moved from US$34 to US$39, which is about a 15% change in the latest model.
-
The revenue growth assumption remains at about 18.20%, with only a minor change at the fourth decimal place.
-
The net profit margin assumption has shifted from 6.27% to about 6.44%.
-
The future P/E assumption has adjusted from 47.16x to about 56.79x.
-
The discount rate is effectively unchanged at 7.24%, with the revised figure rounding to the same level as before.
Never Miss an Update: Follow The Narrative
Narratives link Biodesix's business story to a financial forecast and fair value, so you can see how new data points affect the bigger picture. They update automatically as fresh company news and analyst assumptions are added.
Head over to the Simply Wall St Community and follow the Narrative on Biodesix to stay up to date on:
-
How Biodesix is using an expanded salesforce and higher digital ordering through its Physician Portal and EMR integrations to increase test volumes, retention and recurring revenue while cutting administrative effort.
-
How clinical studies like CLARIFY and ALTITUDE, plus growing Development Services contracts with biopharma partners, support broader adoption of its lung diagnostics and companion diagnostic offerings.
-
Key risks such as ongoing operating losses and cash burn, reliance on a small set of core lung tests like Nodify, reimbursement timing for key assays, and competition from larger diagnostics companies.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BDSX .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
